Background: Asthma patients potentially have impaired adaptive immunity to virus infection. The levels of SARS-CoV-2-specific adaptive immunity between COVID-19 survivors with and without asthma are presently unclear.

Methods: COVID-19 survivors (patients with asthma n=11, with allergies n=8, and COVID-19 only n=17) and non-COVID-19 individuals (asthmatic patients n=10 and healthy controls n=9) were included. The COVID-19 patients were followed up at about 8 months and 16 months after discharge. The clinical characteristics, lymphocyte subsets, memory T cells, and humoral immunity including SARS-CoV-2 specific antibodies, SARS-CoV-2 pseudotyped virus neutralization assay, and memory B cells were analyzed in these subjects.

Results: The strength of virus-specific T cell response in COVID-19 survivors was positively correlated with the percentage of blood eosinophils and Treg cells (r=0.4007, p=0.0188; and r=0.4435, p=0.0086 respectively) at 8-month follow-up. There were no statistical differences in the levels of SARS-CoV-2-specific adaptive immunity between the COVID-19 survivors with, and without, asthma. Compared to those without asthma, the COVID-19 with asthma survivors had higher levels of SARS-CoV-2 specific antibodies (NAbs) at the 8-month follow-up (p<0.05). Moreover, the level of NAbs in COVID-19 survivors was positively correlated with the percentage of Treg and cTfh2 cells (r=0.5037, p=0.002; and r=0.4846, p=0.0141), and negatively correlated with the percentage of Th1 and Th17 cells (r=-0.5701, p=0.0003; and r=-0.3656, p=0.0308), the ratio of Th1/Th2, Th17/Treg, and cTfh1/cTfh2 cell (r=-0.5356, r=-0.5947, r=-0.4485; all p<0.05). The decay rate of NAbs in the COVID-19 survivors with asthma was not significantly different from that of those without asthma at 16-month follow-up.
**INTRODUCTION**

As of October 2021, the Coronavirus disease 2019 (COVID-19) pandemic has been responsible for more than 4.6 million deaths worldwide (1). Disease severity ranges from asymptomatic through to fatal, and data from several studies has suggested that older age and comorbidities, including hypertension, diabetes, and cardiovascular disease, are major risk factors for COVID-19 mortality (2–4).

Asthma is one of the most prevalent chronic airway inflammatory diseases worldwide and is closely related to type 2 immune responses (5). A variety of respiratory viruses, including rhinoviruses, the influenza virus, and coronaviruses, can affect the upper and lower airways and induce asthma attacks (6). Interestingly, existing studies have not indicated that COVID-19 exacerbates asthma or that there has been a high prevalence of asthma among COVID-19 patients (7). It has previously been observed that in most countries, asthmatic patients have usually had similar or lower rates of COVID-19 infection, rather than higher rates, when compared to general populations within the corresponding areas (4, 8–11). However, there is no clear evidence that the severity and mortality rates among COVID-19 patients with asthma are higher than for patients without asthma (12, 13).

Previously, some studies indicated that asthmatic patients may experience an exacerbated inflammatory response and may be at a higher risk of mortality after COVID-19 infection (14–16). While, in another study including COVID-19 patients from the United States, South Korea, and Europe, it was discovered that mortality in COVID-19 patients with and without asthma was similar (17). Moreover, among hospitalized patients 65 years or younger with severe COVID-19, asthma diagnosis was not associated with worse outcomes, regardless of age, obesity, or other high-risk comorbidities (18). Our previous studies showed that the prevalence of asthma in patients with COVID-19 was markedly lower than that reported in the adult population of Wuhan (0.9% vs 6.4%) (4). Overall, we speculate that asthma may be a protective factor for COVID-19 (19–21).

As far as now, there are no related report reveal whether asthma patients experience altered specific immunity against acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While, Jing Li et al. identified elevated levels of KIR+CD8+ T cells, but not CD4+ regulatory T cells, in COVID-19 patients, which were associated with disease severity and vasculitis (22). Another previous literature showed that the stimulation of immune cells with live SARS-CoV-2 induced a rapid decline in the pool of effector memory CD8+ cells, but not CD4+, T cells after recovery from COVID-19 (23). Moreover, Gong et al. demonstrated a close connection between CD4+T cells and antibody production in COVID-19 convalescent patients (24). Cellular and humoral immunity plays an important role in SARS-CoV-2 infection and clinical recovery. Moreover, SARS-CoV-2-specific T cells, B cells, and antibodies may persist more than one year after patients have recovered from SARS-CoV-2 infection and may also predict their re-infection risk (25, 26). Specific immunity in asthmatic patients after recovery from COVID-19 has rarely been reported.

Given the high incidence of both COVID-19 and asthma, and the lack of clinical studies to date, the present study aimed to investigate the levels of SARS-CoV-2-specific humoral and cellular immunity in patients with and without asthma. In addition, this research explored the relationships between these SARS-CoV-2 specific immunity levels and the baseline T lymphocyte subsets and immune polarization of these patients, as well as their clinical features and outcomes from laboratory tests.

**METHODS**

**Study Subjects**

In total, 36 convalescing COVID-19 individuals (who also had asthma n=11, allergies n=8, or COVID-19 only n=17) and age-and sex-matched asthmatic patients (n=10) and healthy donors (n=9) who were not vaccinated with COVID-19 vaccine were recruited. The COVID-19 patients had received positive laboratory test results using the SARS-CoV-2 nucleic acid test between January 2020 to March 2020, in Wuhan, China. Subject to the word limit of the article, other materials and method content are included in the **Supplementary Material**.
RESULTS

Demographic and Baseline Clinical Characteristics

Full demographic and baseline clinical characteristics of participants are detailed in Table 1. There were no significant differences in age, sex, or BMI among the five groups, which was expected as they had been matched for these characteristics. Th2-high asthma was found in 9 of 11 COVID-19 with asthmatic patients and 9 of 10 asthmatic patients not affected by COVID-19. The rate of severe COVID-19 was slightly higher in patients within the COVID-19 only group than patients in the COVID-19 with asthma or allergy groups (47.1% vs 9.1% vs 37.5%, p=0.114). There were no statistical differences in the underlying comorbidities between all participants, besides hypertension, which is higher in COVID-19 with asthma group (p=0.001, Table 1).

Clinical Characteristics, Laboratory Findings, Pulmonary Function, and Radiographic Findings at 8-Month Follow Up

Comparisons in COVID-19 patients 8 months after discharge were conducted. As shown in Table 2, some COVID-19 survivors still had persistent physical and (or) psychological symptoms, but there were no obvious differences between COVID-19 patients with or without asthma. The result of the 6MWD test in COVID-19 patients with asthma were slightly lower than that in the other two groups (p=0.292). Furthermore, there were no significant differences in the laboratory findings between the COVID-19 patients with either asthma, allergies, or COVID-19 only at the 8-month follow-up period.

Pulmonary function tests were completed in all of the COVID-19 patients 8 months following discharge. Compared with the other two COVID-19 groups, patients with asthma plus COVID-19 had a lower MVV% predicted (p=0.0012) and MEF50% predicted (p=0.015), which represented a reduced ventilation reserve capacity and limited small airways functions. It was found that there were no statistical differences in the CT scores between the three COVID-19 groups, however, the proportion of irregular lines on the chest CT imaging 8 months after discharge was higher in COVID-19 with asthma group than in the other two COVID-19 groups (45.5% vs 37.5% vs 35.3%, p=0.031). More detailed information is summarized in Table 2.

Peripheral Blood Lymphocyte Subsets in Subjects

Flow cytometry was used to detect the changes in peripheral blood T lymphocyte subsets in the five groups of participants. The results are presented in Figure 1 and Figure E2 and the gating strategy of flow cytometry is shown in Figure E1. Within CD3^+CD4^+T lymphocytes, CD183^+T cells, CD294^+T cells, CD196^+T cells, and CD25^highCD127^lowT cells were defined as Th1, Th2, Th17, and Treg cells, respectively.

These lymphocyte subsets were detected by flow cytometry at the baseline, 24 hours, and 72 hours after PBS control and SARS-CoV-2 Spike peptide pools (S) stimulation. The T helper cell

TABLE 1 | Demographic and baseline clinical characteristics of subjects.

| Characteristic                              | COVID-19 with Asthma | COVID-19 with Allergy | COVID-19 Asthma | Healthy control | p value |
|--------------------------------------------|----------------------|-----------------------|----------------|-----------------|---------|
| Number                                     | 11                   | 8                     | 17             | 10              | 9       |
| Age (years)                                | 50 (36-71)           | 57 (34.75-70.25)      | 49 (38-68)     | 54.5 (46.75-58.75) | 56 (38.5-63.5) | 0.997   |
| Gender (Female/Male)                       | 7/4                  | 5/3                   | 8/9            | 6/4             | 6/3     | 0.874   |
| BMI (kg/m²)                                | 26.21 ± 3.75         | 22.77 ± 3.46          | 24.45 ± 2.95   | 25.38 ± 3.56    | 24.21 ± 3.93 | 0.282   |
| Smoking history, n (%)                     | 2 (18.2%)            | 2 (25%)               | 2 (11.8%)      | 1 (10%)         | 0 (0%)  | 0.638   |
| Severe COVID-19, n (%)                     | 1 (9.1%)             | 3 (37.5%)             | 8 (47.1%)      | –               | –       | <0.001* |
| Severe asthma, n (%)                       | 3 (27.3%)            | –                     | –              | 2 (20%)         | –       | <0.001* |
| Th2-high asthma, n (%)                     | 9 (81.8%)            | –                     | –              | 9 (90%)         | –       | <0.001* |
| Atopy, n (%)                               | 5 (45.5%)            | 8 (100%)              | 0 (0%)         | 8 (80%)         | 0 (0%)  | <0.001* |

Data were expressed as mean ± SD, median (interquartile range), and No. (%) Multiple groups were compared using one-way analysis of variance (ANOVA) test with Tukey intergroup comparison (normal data) or a Kruskal-Wallis test with a Dunn intergroup comparison (non-normal data). The Fisher exact tests were used to compare ratios. Bold values indicate significant differences (p<0.05).

*: COVID-19 with Asthma vs COVID-19, p < 0.05.
#: COVID-19 with Allergy vs COVID-19, p < 0.05.
§: COVID-19 with Asthma vs COVID-19 with Asthma, p < 0.05.
¶: COVID-19 with Asthma vs COVID-19 with Allergy, p < 0.05.
$#: COVID-19 with Asthma vs Healthy control, p < 0.05.
$§: COVID-19 with Asthma vs Healthy control, p < 0.05.

BMI, body mass index; COPD, chronic obstructive pulmonary disease; CHD, coronary heart disease; CKD, chronic kidney disease.
compartment, median of baseline Th1 cells percentage, and Th1/Th2 ratio decreased significantly in COVID-19 patients with asthma, they were lower than observed in the COVID-19 only, asthma without COVID-19 and healthy control groups (all p<0.05, Figures 1C, G). The frequency of baseline Th2 cells in COVID-19 only group was lower than that in COVID-19 with asthma group (p<0.05, Figure 1D). While no significant differences were observed in the percentages of baseline CD4+ T cells, CD8+ T cells, Th17 cells, Treg cells, CD4+/CD8+ T cell ratio, and Th17/Treg cell ratio among the five groups (Figures 1A, B, E, F, H). At 24-hour, the difference in T lymphocyte subsets in the SARS-CoV-2 S stimulated group and PBS control group were

### Table 2: Characteristics of COVID-19 survivor with/without asthma or allergy at 8-month follow-up.

|                         | COVID-19 with Asthma | COVID-19 with Allergy | COVID-19 | p value |
|-------------------------|----------------------|-----------------------|-----------|---------|
| **Eight months after discharge** |                      |                       |           |         |
| Number                  | 11                   | 8                     | 17        |         |
| **Clinical symptoms**   |                      |                       |           |         |
| PCFS scale grade≥1, n (%) | 4 (36.4%)            | 4 (50%)               | 9 (52.9%) | 0.689   |
| PCFS scale grade≥2, n (%) | 1 (9.1%)             | 2 (25%)               | 4 (23.5%) | 0.642   |
| 6MWD, m                 | 502 ± 95             | 549.6 ± 88.6          | 554.8 ± 83.7 | 0.292   |
| **Laboratory data**     |                      |                       |           |         |
| WBC (× 10^9/L)          |                      |                       |           |         |
| Lymphocyte count (× 10^9/L) | 1.77 (1.56-2.00)     | 1.985 (1.53-2.38)    | 2.21 (1.77-2.78) | 0.421   |
| Eosinophil count (× 10^9/L) | 0.2 (0.07-0.33)     | 0.18 (0.06-0.28)     | 0.13 (0.06-0.21) | 0.796   |
| T-IgE (KU/I)            | 134 (71.2-288)       | 85.4 (17.78-100)     | 100 (43.45-100) | 0.146   |
| **SARS-CoV-2-specific antibodies** |            |                       |           |         |
| IgG (S/CO)              | 7.82 (5.05-10.14)    | 6.55 (3.56-8.07)     | 6.31 (2.97-8.56) | 0.300   |
| IgM (S/CO)              | 0.2 (0.08-0.54)      | 0.165 (0.11-0.27)    | 0.23 (0.065-0.7) | 0.812   |
| **Pulmonary function**  |                      |                       |           |         |
| FEV1% predicted         | 91.0 ± 25.1          | 106.2 ± 14            | 104.8 ± 14.6 | 0.116   |
| FVC% predicted          | 105.8 ± 22.9         | 115.1 ± 16.6          | 113.4 ± 17.4 | 0.491   |
| FEV1/FVC, %             | 71.2 ± 12.0          | 76.8 ± 77.2           | 76.3 ± 6.9 | 0.291   |
| MEF50% predicted        | 55.5 ± 27.3          | 84.7 ± 17.86          | 74.8 ± 18.5 | 0.015*  |
| MEF25% predicted        | 43.2 (16.2-48.2)     | 57.1 (39.5-80.7)      | 48.1 (35.5-59.7) | 0.218   |
| MMEF75/25% predicted    | 49.5 ± 25.1          | 68.2 ± 25.6           | 65.5 ± 18.6 | 0.142   |
| MVV% predicted          | 91.7 ± 16.1          | 111.5 ± 14.4          | 115.6 ± 15.6 | 0.0012* |
| TLC% predicted          | 96.4 ± 11.5          | 101.6 ± 9.2           | 98.1 ± 6.8 | 0.463   |
| DLCO% predicted         | 85.8 ± 13.2          | 83.7 ± 11.0           | 89.4 ± 14.9 | 0.586   |
| DLCO/VA% predicted      | 92.0 ± 11.8          | 85.3 ± 14.8           | 93.7 ± 14.0 | 0.361   |
| **Chest HRCT**          |                      |                       |           |         |
| CT score                | 2 (1-3)              | 0.5 (0-1.75)          | 1 (0-3.5) | 0.445   |
| Abnormal HRCT (CT score≥5), n (%) | 2 (18.2%)           | 1 (12.5%)            | 3 (17.6%) | >0.999  |
| GGO, n (%)              | 5 (45.5%)            | 3 (37.5%)            | 6 (35.3%) | 0.965   |
| Irregular lines, n (%)  | 9 (81.8%)            | 2 (25%)               | 7 (41.2%) | <0.001* |
| Consolidation, n (%)    | 0 (0%)               | 0 (0%)               | 0 (0%)    | –       |
| Interlobular septal thickening, n (%) | 0 (0%)           | 0 (0%)               | 0 (0%)    | –       |
| Subpleural line, n (%)  | 0 (0%)               | 0 (0%)               | 0 (0%)    | –       |
| Reticular pattern, n (%)| 0 (0%)               | 0 (0%)               | 1 (5.9%)  | >0.999  |
| **Treatment post-discharge** |                      |                       |           |         |
| ICS/LABA, n (%)         | 6 (55%)              | 0 (0%)                | 0 (0%)    | <0.001* |
| ICS dose (BDP equivalent, ug/d) | 200 (0-400)        | –                     | –         | –       |
| Systemic glucocorticoid, n (%) | 0 (0%)           | 0 (0%)               | 0 (0%)    | –       |
| LTRA, n (%)             | 1 (9%)               | 1 (12.5%)            | 1 (5.9%)  | >0.999  |
| ACEI/ARB, n (%)         | 4 (36.4%)            | 0 (0%)               | 3 (17.6%) | 0.182   |
| Antibiotics, n (%)      | 0 (0%)               | 0 (0%)               | 0 (0%)    | –       |
| Anticoagulants, n (%)   | 0 (0%)               | 0 (0%)               | 1 (5.9%)  | >0.999  |
| Immunosuppressive drug, n (%) | 0 (0%)           | 0 (0%)               | 1 (5.9%)  | >0.999  |
| Antiviral drugs, n (%)  | 0 (0%)               | 0 (0%)               | 0 (0%)    | –       |
| **Time from discharge to visit 1, d** | 239 ± 12            | 246 ± 15             | 245 ± 13  | 0.491   |

Data were expressed as mean ± SD, median (interquartile range), or No. (%). Multiple groups were compared using one-way analysis of variance (ANOVA) test with Tukey intergroup comparison (normal data) or a Kruskal-Wallis test with a Dunn intergroup comparison (non-normal data). Bold values indicate significant differences (p<0.05).

*: COVID-19 with Asthma vs COVID-19, p < 0.05.
#: COVID-19 with Asthma vs COVID-19 with Allergy, p < 0.05.
¶: COVID-19 with Asthma vs COVID-19 with Allergy, p < 0.05.

PCFS scale, post-COVID-19 functional status scale; 6MWD, six-minute walk distance; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; MEF50, maximal expiratory flow at 50% of FVC; MEF25, maximal expiratory flow at 25% of FVC; MMEF75/25, maximal mid-expiratory flow between 75% and 25% of FVC; MVV, maximum voluntary ventilation; TLC, total lung capacity; DLCO, diffusion capacity of the lung for carbon monoxide; DLCO/VA, ratio of carbon monoxide diffusion capacity to alveolar ventilation; HRCT, high-resolution computed tomography; GGO, ground glass opacity; ICS/LABA, combination inhaled corticosteroids plus long-acting β-agonists; BDP, beclomethasone dipropionate; LTRA, leukotriene receptor-antagonist; ACEI/ARB, angiotensin converting enzyme inhibition/angiotensin receptor blocker.
similar to the baseline results (Figures E2A, B). Moreover, no significant differences in the proportions of CD4+ T, CD8+ T, Th1, Th2, Th17, or Treg cells were found in the 72 hours S stimulated group compared with the PBS control group (Figures 1I–N). The ratios of Th1/Th2 cells in the COVID-19 with asthma group was still lower (p=0.015) at 72 hours after S stimulation (Figure 1O). At the same time, the experimental observation found that the Th17/Treg ratio in the COVID-19 group was lower than that observed in the asthma group (non-COVID-19) and healthy control group after 72 hours of S stimulation (Figure 1P).

In addition, the proliferation of T lymphocyte subsets within the five groups were detected using CFSE assays at 72 hours after S stimulation or a PBS control. There was no obvious proliferation of T lymphocyte subsets in the peripheral blood of all subjects (Figure E3).
SARS-CoV-2 Specific Memory T Cell Responses Among COVID-19 Survivors and Controls

Two methods were used to detect SARS-CoV-2 specific memory T cell responses. Intracellular cytokine (ICS) analysis was utilized to assess SARS-CoV-2-specific CD4+ and CD8+ T cells in the peripheral blood from all participants. Interferon (IFN)-γ ELISA analysis was used to determine the magnitude of the global SARS-CoV-2-specific memory T cell response.

Although most COVID-19 survivors have specific T cell responses to SARS-CoV-2, the results from the virus-specific spike/control ratio of CD4+T cells and CD8+T cells in the five groups were not statistically significantly different (Figures 2A–D). However, when the 17 COVID-19 survivors were divided into...
9 non-severe patients and 8 severe patients, the median ratios of spike/control IFN-γ percentages of CD4+ and CD8+ T cell in the severe COVID-19 group were higher than those in the non-severe group (Figures E4A, B).

IFN-γ levels were increased in the total T cell culture supernatants from COVID-19 survivors 72h after S stimulation compared to the PBS control (Figure 2E). Among the 11 patients in the COVID-19 with asthma group, one patient’s IFN-γ level exceeded the detected value range, and the remaining 10 patients all showed increased IFN-γ levels (p<0.01). In the COVID-19 with allergy group, 1 in 8 patients had an IFN-γ beyond the detection range, and 5 of the remaining 7 patients had IFN-γ values which increased in the spike stimulation group when compared with the PBS control group (p=0.055). IFN-γ levels also increased in 16 of the 17 patients in the COVID-19 only spike-stimulated group compared with the PBS control group (p<0.0001). There were no significant differences in IFN-γ levels between the PBS control and S stimulation in asthma (non-COVID-19) patients (Figures E4C–E).

Correlation Analyses

To explore the relationships between SARS-CoV-2-specific T cell responses and memory humoral immunity with Th2 inflammation, immune imbalance, and percentages of cTfh cells in COVID-19 survivors at the 8-month follow-up, further correlation analysis was conducted.

As shown in Figure 5, the strength of the SARS-CoV-2-specific T cell response was directly proportional to the percentages of eosinophils and Treg cells (r=0.5701 and -0.5356, respectively, Figures 5B, E). However, no significant correlation was found between IgG and the SARS-CoV-2-specific T cell response (Figure 5B). Additionally, no significant correlation was found between SARS-CoV-2-specific T cell responses and lymphocyte subsets (Figures E5A–E).

Intriguingly, the results of the correlational analysis showed that the IC50 values of all COVID-19 survivors were negatively correlated with Th1 cells and the Th1/Th2 ratio, with R values of -0.5701 and -0.5356, respectively, and P values of 0.0003 and 0.0009, respectively (Figures 5D, F). The IC50 value was positively correlated with the proportion of Treg cells (r=0.5037, p=0.002) whereas it was negatively correlated with the proportion of Th17 cells (r=0.3656, p=0.0308) and Th1/Treg ratio (r=-0.5947, p=0.002) (Figures 5G–I). Moreover, the IC50 value was positively correlated with cTfh2% and negatively correlated with the ratio of cTfh1/cTfh2 (all p<0.05, Figures 5K, L). Although not statistically
significant, there was a trend of negative correlation between cTfh1 cells and IC50 value (Figure 5J). There was no significant correlation between the IC50 value with the percentage of eosinophils or IgE (Figures E5F, H).

**DISCUSSION**

In this study, we described and compared the differences in clinical characteristics, lymphocyte subsets, and levels of SARS-CoV-2-specific cellular and humoral immunity among COVID-19 survivors with and without asthma. Our research results suggest that the survivors with asthmatic comorbidity had higher levels of SARS-CoV-2-specific NAbS after eight months of recovery from COVID-19, and that the level of NAbS was related to the patient’s basic immune Th2/Th1 polarization status. Nevertheless, there were no significant differences in SARS-CoV-2-specific cellular immunity levels between patients 8 months after recovery from COVID-19 with and without asthma.
Eight months after discharge, some COVID-19 survivors still had persistent symptoms, abnormal lung diffusion function, and abnormal CT scores. These results are consistent with those of a previous longitudinal follow-up study (27). However, the incidence of these abnormalities in the present study did not differ significantly between COVID-19 survivors with or without asthma comorbidity. The pulmonary ventilation function of the COVID-19 survivors with asthma comorbidity was lower than that of those without asthma, which may be related to asthma itself.

The specific memory immunity of SARS-CoV-2 in COVID-19 survivors is closely related to the risk of SARS-CoV-2 reinfection and the outcome of COVID-19 (28, 29). However, little information is about the memory immune of SARS-CoV-2 in COVID-19 survivors with asthma. Our findings suggest that SARS-CoV-2-specific memory T cells are still present in the majority of COVID-19 survivors 8 months after discharge, which is similar to previous studies (30, 31). However, there was no significant difference in the levels of SARS-CoV-2-specific T cell responses between COVID-19 survivors with asthma and those without asthma. Furthermore, we found that the levels of SARS-CoV-2-specific T cell memory responses were positively correlated with eosinophil percentages in 34 COVID-19 survivors at 8 months post-discharge. Eosinophils play an important role in asthma and allergic diseases and have a potential role in promoting virus clearance and antiviral host defense (32, 33). Previous observations have demonstrated that eosinophils respond to airway viruses. Influenza A virus peptide stimulated eosinophils can induce T cell activation and promote host cellular immunity, which is consistent with our results (33, 34). The proportion of eosinophils in peripheral blood from severely affected COVID-19 patients is reduced, which in turn is related to the progression and prognosis of severe COVID-19 patients (35–37). A retrospective study reported by Ferastaoroar et al. concluded that increased eosinophils in asthmatic patients during hospitalization were associated with reduced mortality from COVID-19 (38). COVID-19 survivors with elevated eosinophils may therefore have a reduced risk of severe reinfection with SARS-CoV-2.

Th2/Th1 imbalance may affect patients’ susceptibility to SARS-CoV-2 and clinical outcomes in SARS-CoV-2 infection (39, 40). Th2 cytokines can down-regulate the expression of airway epithelial angiotensin-converting enzyme 2 (ACE2) (21, 41, 42), which is the primary receptor of SARS-CoV-2, thereby reducing the prevalence and severity of COVID-19 patients. On the other hand, COPD inflammatory airway disease, which is typically Th1-skewed immunity, had an increased rate of COVID-19 infection and increased severity of the disease (20, 43). The majority of asthmatics demonstrated a predominantly Th2 immune response (44, 45). Our study explored the basic immune cell subsets of COVID-19 patients at the 8-month follow-up and found that the percentage of Th2 cells at baseline in COVID-19 patients with asthma was higher than in patients without asthma, and the Th1/Th2 ratio was lower than in patients without asthma. It is worth noting that although previous studies have shown that Th1 type cellular immunity plays a major role in the body’s fight against SARS-COV-2 infection (46, 47), in our data, there is no correlation between Th2/Th1 imbalance and SARS-CoV-2-specific cellular immunity in COVID-19 patients during recovery.

At 8 months post-discharge, the level of NAbs in the COVID-19 survivors with asthma was higher than for those without asthma. NAbs play an important role in preventing SARS-CoV-2 infection, and the level of NAbs is positively correlated with the
severity of this disease (48, 49). Consistent with previously published literature, the present research found that the IC50 value in severe COVID-19 convalescent patients was higher than that in non-severe patients at the 8-month follow-up stage (50) (Figure 3D). COVID-19 survivors with asthma had a lower rate of severe COVID-19 during hospitalization, but a higher level of SARS-CoV-2-specific NAbs eight months after discharge, which strengthens the evidence that COVID-19 survivors with asthma had a higher level of specific humoral immunity than that without asthma. What’s more, there was no significant difference in the NAbs decay rates between COVID-19 survivors with asthma and those without asthma.

We carried out further research to discover the reasons behind this phenomenon indicating higher levels of NAbs in COVID-19 survivors with asthma. There was no significant difference in the levels of SARS-CoV-2 specific MBCs between the COVID-19 survivors with asthma and those without asthma at the 8-month follow-up. Moreover, we found that the value of IC50 was directly proportional to the percentage of cTfh2 cells and inversely proportional to the ratio of cTfh1/cTfh2 cells. No positive association was found between NAbs and the proportion of cTfh1 cells, unlike previous findings regarding COVID-19 survivors at the one month of follow-up (24). The cTfh cells are a unique subset of CD4+ T cells, whose main role is to help B cells establish germinal center responses and produce high-affinity antibodies (51, 52). Our study depicts a close association between the ratios of cTfh1/cTfh2 cells with the SARS-CoV-2-specific antibody production in COVID-19 survivors.

In addition, the values of IC50 in COVID-19 convalescent individuals was positively correlated with the percentage of Treg cells and negatively correlated with the percentage of Th1 and Th17 cells, Th1/Th2, and Th17/Treg ratios. These results seem to
be consistent with other research which found Ab-negative recovered COVID-19 individuals had higher Th17 cells percentages, and higher Th1/Th2 and Th17/Treg ratios, compared with Ab-positive individuals (53). Previous studies on immunity to infection with SARS-CoV-2 have shown that CD4+ T cell responses are mainly polarized to the Th1 type (54). Th2 polarized immunity can not only stimulate antibody production but also suppress Th1 cell-mediated immunity (55, 56). This might explain why the Th1/Th2 ratio was inversely correlated with neutralizing antibody levels. Increased Th17 response and disturbance ratios of Treg/Th17 may be contributed to the excessive inflammation of COVID-19 (57, 58). COVID-19 survivors with Th17-polarized immune responses and Th17/Treg dysfunction have lower levels of specific humoral immunity, possibly partly at the expense of Th2 humoral immunity (59). Our results confirmed that the Th17/Treg immune balance plays an important role in the specific immunity of SARS-CoV-2 infection.

Treg cells are a class of CD4+ T cells, which play a critical role in maintaining immune homeostasis (60, 61). In our study, Treg cells exhibited a strong positive correlation with the strength of cellular and humoral memory immune response to SARS-CoV-2. Treg cells play an important role in the pathogenesis of COVID-19 by inhibiting adaptive immune responses. In addition, the percentage of Treg cells in patients with severe COVID-19 showed a decreasing trend (62). COVID-19 patients exhibit a heavily hyperinflammatory milieu during the active phase of the disease, accompanied by high consumption of circulating Treg cells, so we speculate that Treg cells in recovered donors show a feedback increase during the convalescence stage. Meanwhile, severe COVID-19 patients have stronger SARS-CoV-2-specific immune response during recovery (63, 64), which may partly explain the positive correlation between the proportion of Treg cells and SARS-CoV-2-specific T cell immunity and NAbs in COVID-19 patients after 8 months of recovery. However, the specific mechanism of action of Treg cells in SARS-CoV-2 immune memory needs to be further explored.

ICS, alone or combination with bronchodilators, are used extensively in the treatment of asthma and affect human immunity. Inhaled or systemic can inhibit the production of the critical antiviral mediators’ Type I and III interferons (65). In vitro studies have suggested that corticosteroids may impair antiviral innate immune responses (66, 67). A result of a previous study indicated that in mice models of allergic asthma, inhaled glucocorticoids prevented the response of CD8+ T cells (68). However, as corticosteroids suppress type 2 inflammation, their use in COVID-19 with asthmatic patients may thus lead to a beneficial effect (69). Furthermore, in patients with immune deficiency diseases, glucocorticoids may affect the activation of B cells through various pathways, thereby reducing the production of antibodies and impairing humoral immunity (70, 71). In our study, 6 out of 11 (55%) asthma patients who recovered from COVID-19 were treated with ICS/LABA. There were no significant differences in the SARS-CoV-2-specific cellular and humoral immune memory between COVID-19 survivors treated with and without ICS/LABA (Figure E7).

The present study has several limitations. Firstly, our cohort is of relatively small size, because there are fewer COVID-19 patients with asthma that can be recruited. A larger cohort is needed to corroborate this issue. Secondly, this research was restricted by analyzing SARS-CoV-2-specific cells to those recognizing the spike protein, which elicits a limited CD4+ or CD8+ T cell response. Besides this, we did not perform CXCR5-CD45RA+/CD45RO+ gating strategies to rigorously definite effector T cells, which should be improved in the future study. Thirdly, our experimental methods for detecting SARS-CoV-2 specific T cells and memory B cells are not sufficiently comprehensive. The ELISPOT method can supplement the evaluation of the cellular immune memory. Humoral memory responses can be assessed by analyzing changes in the proportion of MBC and changes in the level of neutralizing antibodies released by MBC after antigenic peptide stimulation. Last, our results were applied to adult patients and mostly Th2-high asthma. Therefore, pediatric asthma or Th2-low asthma within COVID-19 patients may behave differently with regards to immune intensity and duration thereof.

The level of NAbs in COVID-19 survivors with asthma was higher than for those without asthma at 8 months follow-up. In the future, further investigation will help improve our understanding of the interaction between immune polarization and immune protection against SARS-CoV-2.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

MX, RG, JY and RZ conceived the study and planned the experiments. JY, LC, BW and ML carried out the experiments. JY, WB, SZ, LQ, CZ, SX, QJ, LY, QX, and RZ supported the clinical aspects of the study. JY, LC, RG and MX analyzed the data. MX, RG, JY and LC participated in data interpretation and scientific discussion. JY and MX drafted and revised the manuscript. All the authors reviewed and approved the final
version of the manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

**FUNDING**

This research was jointly funded by the CAS-VPST Silk Road Science Fund 2021 (GJHZ20211134), the National Natural Science Foundation of China (32170949) and the Natural Science Foundation of Hubei Province of China (2019CFA076).

**REFERENCES**

1. WHO Coronavirus (COVID-19) Dashboard. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
2. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of Comorbidities and its Effects on Patients Infected With SARS-CoV-2: A Systematic Review and Meta-Analysis. *Int J Infect Dis* (2020) 94:91–5. doi: 10.1016/j.ijid.2020.03.017
3. Williamson EF, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors Associated With COVID-19-Related Death Using OpenSAFEly. *Nature* (2020) 584(7821):430–6. doi: 10.1038/s41586-020-2521-4
4. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Clinical Characteristics and Outcomes of COVID-19 Patients With and Without Asthma From the United States, South Korea, and Europe. *J Asthma Off J Assoc Care Asthma* (2021) 11:1–11. doi: 10.1080/02770903.2021.205392
5. Lovinsky-Desir S, Deshpande DR, De A, Murray L, Stingone JA, Chan A, et al. Asthma Among Hospitalized Patients With COVID-19 and Related Outcomes. *J Allergy Clin Immunol* (2020) 146(5):1027–34. doi: 10.1016/j.jaci.2020.07.026
6. Liu S, Cao Y, Du T, Zhi Y. Prevalence of Comorbid Asthma and Related Outcomes in COVID-19: A Systematic Review and Meta-Analysis. *J Allergy Clin Immunol In Prac* (2021) 9(2):693–701. doi: 10.1016/j.jaip.2020.11.054
7. Song J, Zeng M, Wang H, Qin C, Hou HY, Sun ZY, et al. Distinct Effects of Asthma and COPD Comorbidity on Disease Expression and Outcome in Patients With COVID-19. *Allergy* (2021) 76(2):483–96. doi: 10.1111/all.14517
8. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA, et al. Association of Respiratory Asthma, Asthma, and Expression of the SARS-CoV-2 Receptor ACE2. *J Allergy Clin Immunol* (2020) 146(1):203–6. doi: 10.1016/j.jaci.2020.04.009
9. Li J, Zaslavsky M, Su Y, Guo J, Sikora MJ, van Unen V, et al. KIR(+)CD8(+) T Cells Suppress Pathogenic T Cells and are Active in Autoimmune Diseases and COVID-19. *Science* (2022) 376(6590):eabi9591. doi: 10.1126/science.abi9591
10. Matyszenko V, Isakovsk-Sivak I, Kudryanets G, Goshina A, Chistyakova A, Stepanova E, et al. Detection of Ifnγ-Secreting CD4(+) and CD8(+) Memory T Cells in COVID-19 Convalescents After Simulation of Peripheral Blood Mononuclear Cells With Live SARS-CoV-2. *Virology* (2021) 13(8):1490. doi: 10.3390/v13081490
11. Gong F, Dai Y, Zheng T, Cheng L, Zhao D, Wang H, et al. Peripheral CD4+ T Cell Subsets and Antibody Response in COVID-19 Convalescent Individuals. *J Clin Invest* (2020) 130(12):6588–99. doi: 10.1172/jci141054
12. Stephens DS, McElrath MJ. COVID-19 and the Path to Immunity. *Jama* (2020) 324(13):1279–81. doi: 10.1001/jama.2020.16656
13. Hou H, Zhang Y, Tang G, Luo Y, Liu W, Cheng C, et al. Immunologic Memory to SARS-CoV-2 in Convalescent COVID-19 Patients at 1 Year Postinfection. *J Allergy Clin Immunol* (2021) 148(6):1481–92. doi: 10.1016/j.jaci.2021.09.008
14. Wu X, Liu X, Zhou Y, Yu H, Li R, Zhan Q, et al. 3-Month, 6-Month, 9-Month, and 12-Month Respiratory Outcomes in Patients Following COVID-19-Related Hospitalisation: A Prospective Study. *Lancet Respir Med* (2021) 9(7):747–54. doi: 10.1016/s2213-2600(21)00174-0
15. Seder RA, Darrah PA, Roederer M. T-Cell Quality in Memory and Protection: Implications for Vaccine Design. *Nat Rev Immunol* (2008) 8(4):247–58. doi: 10.1038/nri2274
16. Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, et al. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. *Immunity* (2020) 52(6):971–977.e3. doi: 10.1016/j.immuni.2020.04.023
17. Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD, et al. Functional SARS-CoV-2-Specific Immune Memory Persists After Mild COVID-19. *Cell* (2021) 184(1):169–183.e17. doi: 10.1016/j.cell.2020.11.029

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.947724/full#supplementary-material
31. Sandberg JT, Varnaite R, Christ W, Chen P, Muvva JR, Maleki KT, et al. SARS-CoV-2-Specific Humoral and Cellular Immunity Persists Through 9 Months Irrespective of COVID-19 Severity at Hospitalisation. *Clin Trans Immunol* (2021) 10(7):33. doi: 10.1002/cti.21306

32. Rosenben HF, Dyer KD, Domachowske JB. Respiratory Viruses and Eosinophils: Exploring the Connections. *Antiviral Res* (2009) 83(1):1–9. doi: 10.1016/j.antiviral.2009.04.005

33. Samarasinghe AE, Melo RC, LeMessurier KS, Listovskaya E, et al. Stop COVID Cohort: An Observational Study of 3480 Patients Admitted to Hospital in the UK. *Respirol (Carlton Vic)* (2021) 26(4):648–659. doi: 10.1111/res.13088

34. Varnaite J, Varnaite L. Allergy and Eosinophilia in Asthma Patients Is Protective Against Severe COVID-19 Illness. *J Allergy Clin Immunol In Pract* (2021) 9(3):1152–1162.e3. doi: 10.1016/j.jaip.2020.12.045

35. Pavel AB, Glickman JW, Michels JR, Kim-Shulze S, Miller RL, Guttman-Yassky E. Th2/Th1 Cytokine Imbalance Is Associated With Higher COVID-19 Risk Mortality. *Front Genet* (2021) 12:70692. doi: 10.3389/fgen.2021.70692

36. Gil-Etayo FJ, Saérez-Fernández P, Cabrera-Marrante O, Arroyo D, Garciaño S, Naranjo L, et al. T-Helper Cell Subset Response Is a Determining Factor in COVID-19 Progression. *Front Cell Infect Microbiol* (2021) 11:624483. doi: 10.3389/fcimb.2021.624483

37. Wark PAB, Pathinayake PS, Kaiko G, Nichol K, Ali A, Chen L, et al. ACE2 Expression is Elevated in Airway Epithelial Cells From Older and Male Healthy Individuals But Reduced in Asthma. *Respir (Carlton Vic)* (2021) 26(5):442–51. doi: 10.1111 resp.14003

38. Kimura H, Francisco D, Conway M, Martinez FD, Vercelli D, Polverino F, et al. Correlates of Protection Against SARS-CoV-2 Antigens With Virus Neutralizing Antibodies and Symptomatic Severity in a German COVID-19 Cohort. *Emerging Microbes Infect* (2021) 10(1):774–81. doi: 10.1002/22221751.201919373

39. Eisenbarth SC, Baumjoehann D, Craft J, Fazilleau N, Ma CS, Tangye SG, et al. CD4(+) T Cells That Help B Cells - a Proposal for Uniform Nomenclature. *Trends Immunol* (2021) 42(8):658–69. doi: 10.1016/j.it.2021.06.003

40. Van Horn SR, Farrar JD. Interferon at the Crossroads of Allergy and Influenza A Virus. *J Immunol (Baltimore Md 1950)* (2008) 122(1):69. doi: 10.4049/jimmunol.1600787

41. Netz MD, Carroll ML, Li H, Poh AM, Kirkegaard D, Towers M, et al. Budesonide and Formoterol Reduce Early Invasive Anti-Viral Immune Responses In Vitro. *PLoS One* (2011) 6(11):e27898. doi: 10.1371/journal.pone.0027898

42. Simpson JL, Carroll M, Yang IA, Reynolds PN, Hodge S, James AL, et al. Reduced Interferon Production in Poorly Controlled Asthma Is Induced Eosinophil Mediator Release Requires Antigen-Presenting and CD4(+) T Cells That Help B Cells - a Proposal for Uniform Nomenclature. *Trends Immunol* (2021) 42(8):658–69. doi: 10.1016/j.it.2021.06.003
Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Chen, Yue, Zhang, Bai, Qin, Zhang, Wu, Li, Xu, Jiang, Yang, Xu, Zhu, Xie and Gong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.